Dr. Gilles Montalescot, of Pitié-Salpêtrière Hospital in Paris, discusses the results of the ATLANTIS trial with Dr. Ron Waksman. The study, presented as a late-breaking trial at ACC.21 Virtual, showed that the blood thinner apixaban was not superior to standard of care following transcatheter aortic valve replacement in terms of net clinical benefits but may remain useful for patients with an indication for oral anticoagulation.